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Purpose: To investigate the interacting effects of co-administration of Carica papaya leaf extract on the 
hypoglycemic activity of metformin and glimepiride in an animal model. 
Method: Experimental factorial design was used to evaluate the individual and interaction influence of 
three variables ie nature (N), dose administered (C) and duration of administration (D), in a 23(=8) 
employed at two levels - ‘’high’’ and ‘‘low’’ - on blood glucose of diabetic rats on administration of 
ethanolic leaf extract of Carica papaya and two hypoglycemic agents, metformin and glimepiride. 
Unpaired t-test was used to test for significant difference due to administration of the combination 
Results: Extract of Carica papaya at 5.0 mg/kg produced significant blood glucose reduction with no 
significant reduction at the higher dose of 10 mg/kg (p>0.05). Changing nature from “low” (Carica 
papaya extract) to “high” (glimepiride or metformin) did not significantly change hypoglycemic activity. 
Generally, the ranking of the interacting effects was ND>CD>>NC for glimepiride/extract, and 
CD>ND>NC for metformin/extract. Administration of higher dose of the extract led to significant (p<0.01) 
increase in onset of activity of glimepiride. The onset of activity of metformin was not affected, but a 
significant lowering (p<0.05) of blood glucose was observed at 24 hr with all combinations of extract and 
metformin.  
Conclusion: Leaf extract of Carica papaya significantly delays the onset of hypoglycaemic activity of 
glimepiride, and increases the hypoglycaemic effect of metformin with the variables interacting 
differently for each drug-extract combinations. 
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INTRODUCTION 
Diabetes mellitus is a chronic disease caused by 
inherited or acquired deficiency of insulin 
production or resistance to action of the 
produced insulin 1. This results in an increased 
concentration of glucose in the blood usually 
leading to organ damage 2. Much of the increase 
in incidence of diabetes worldwide occurs in 
developing countries with causes such as aging, 
unhealthy diets, obesity and sedentary lifestyle, 
with malnutrition-related causes playing 
predominant roles 2, 3. 
Herbs such as bittermelon, garlic and psyllium 
seeds have been shown to possess antidiabetic 
activities and when administered concurrently 
with allopathic drugs, could lead to interactions 
with increased likelihood of hypoglycaemia 4. 
The co administration stems from the fact that it 
is believed sometimes that use of herbs is 
harmless, even though some drugs with narrow 
therapeutic index were developed from plants 5. 
In spite of this, it is common to find patients in 
both industrialised and developing countries 
using herbs with prescribed drugs 6,7, without 
informing their health care practitioners. 
Investigations in Nigeria 7,8, have shown that a 
significant number of patients tend to co-
administer herbal medications with allopathic 
drugs.  
Carica papaya Linn (Caricaceae), known as 
pawpaw and papaya 9, is common in tropical 
and sub-tropical countries, and some diabetic 
patients concurrently take leaf extracts of Carica 
papaya with oral hypoglycaemic prescription 
drugs 8. Its biologically active constituents 
include chymopapain and papain which are used 
in the treatment of arthritis and digestive 
disorders. In folkloric medicine, extracts of the 
fruits are used for a variety of medicinal 
purposes ranging from treatment of ringworm, 
malaria and hypertension 10, while extracts of 
unripe fruit have been used in treatment of 
diabetes 11,12.  
In spite of the concurrent use of the extract of 
Carica papaya with prescription oral 
hypoglycemic agents in some patients 7,8, there 
is a dearth of literature on the effects of the 
extract on activity of oral hypoglycaemic agents. 
Thus, the objective of this study was to 
investigate the effect of Carica papaya ethanolic 
leaf extracts on hypoglycemic activity of two oral 
hypoglycemic agents namely glimepiride and 




Carica papaya Linn (Caricaceae) leaves were 
collected from the Botanical Gardens (University 
of Ibadan) and authenticated at the Department 
of Pharmacognosy of the University of Ibadan, 
Nigeria. Herbarium specimen with voucher no 
312 were submitted. Young fresh leaves were 
dried in an oven at 40 oC for 48 hr, powdered, 
and 500 g of the powdered leaves was extracted 
with 2 L of 96% ethanol for 24 hr. Repeat 
extraction was done thrice, and the extract 
obtained was pooled, filtered and distilled. The 
residue obtained was dissolved in 20 ml of 
Tween 80 to obtain appropriate concentrations. 
 
Preparation of oral hypoglycemics 
Stock solutions of glimepiride (Aventis Pharm., 
Lagos), and metformin (Nigerian German 
Chemical PLC, Lagos) were prepared by 
triturating the pure powder of the drugs in 20% 
Tween 80. Further dilutions were made with 
distilled water.  
 
Experimental animals 
Healthy male wistar rats weighing between 140-
220 g (180.56 ± 24.91) were obtained from the 
animal house of the College of Medicine, 
University of Ibadan, Nigeria. Animals were kept 
in cages and fed standard commercial diet and 
water ad libitum. Experiments were performed 
according to the guide for care and use of 
laboratory animals. Weights of the rats were 
monitored throughout the period of the 
experiment. In the appropriate groups, 180 
mg/kg alloxan monohydrate (Sigma Chemical 
Company, USA) administered intraperitoneally 
was used to induce diabetes in the animals. 
 
Determination of the Blood Glucose 
Glucometer (ACU-Chek®, Johnson–Johnson, 
California, USA) was used for the determination 
of the blood glucose level of the rats. Blood 
samples were obtained from the cut tail-tip of 
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conscious rat. Basal and 48 hr post-induction 
blood glucose levels of the animals were 
recorded. Thereafter, the extract, drug or drug-
extract combinations were administered daily for 
periods of “short” and “long” duration of 3 or 7 
days, respectively. Blood glucose levels were 
measured at 2 hr, 12 hr, 24 hr, 72 hr and where 
appropriate, 168 hr. 
 
Experimental Protocols 
Factorial experimental design13,14,15,16, which can 
be used to determine factors influencing the 
quantifiable outcome or response of a study, and 
the levels of the factors that will maximise the 
response obtained, was used in this study to 
evaluate the effect of three independent 
variables on the response, i.e., blood glucose 
levels of diabetic rats treated with combination of 
drug-extract. The magnitudes of interaction 
between the factors were also evaluated. The 
relative significance of the interactions between 
the variables or the factors influencing the 
outcome of the experiment, and importance of 
each variable on the measured response (blood 
glucose) were evaluated. 
The variables investigated in this study are 
Nature of drug (N), Dose (C) and Duration (D) at 
“low” level denoted by the subscript L and “high” 
level denoted by the subscript H on the blood 
glucose level of alloxan-induced diabetic rats. 
The extract was assigned “low” nature (23 = 8) 
factorial design (NL) and each drug, “high” nature 
(NH). These factors were combined in a two by 
three combinations to study the individual and 
interaction effects of the factors on the blood 
glucose level. The resulting combinations were 
NHCLDH, NHCLDL, NHCHDH, NHCHDL, NLCLDH, 
NLCLDL, NLCHDH, and NLCHDL. 
 
The animals were divided into several groups. 
All the animals except those administered 20% 
Tween 80 only were fasted for 20 hr before 
administering 180mg/kg intraperitoneal alloxan 
monohydrate. The diabetic state of each rat was 
assessed by blood glucose level which was 
measured 48 hr post-alloxan administration. 
Four animals per group, which presented with 
significant increase up to 10 mmol/L blood 
glucose levels, were used for the experiment.  
Each animal in each group was administered 5 
mg/kg (“low” dose, CL) or 10 mg/kg (“high” dose, 
CH) of the extract (NL); glimepiride, “low” - 0.2 
mg/kg, “high” - 0.4 mg/kg; metformin, “low”- 50 
mg/kg, “high”- 100 mg/kg for either 3 days (“low” 
duration, DL) or 7days (“high” duration, DH). The 
“low” and “high” doses of the drugs were chosen 
based on prior studies done on animal models 
17,18,19. Another set of four groups of animals 
were administered glimepiride-extract 
combinations of “high”-“high”, “high”-“low”, “low”-
“high”, and “low”-“low” doses for 3 days (“low”) 
and 7 days “(high”) duration. This was repeated 
for metformin. Control animals were 
administered 0.1 ml 20% Tween 80, extract (5 or 
10 mg/kg), glimepiride (0.2 or 0.4 mg/kg), or 
metformin (50 or 100 mg/kg) for the duration of 
the experiments. Blood glucose levels of diabetic 
rats were used to calculate the independent and 
interaction coefficients of the variables. 
 
Determining the Individual Effect 
The individual effect of increasing any of the 
variables from its “low” to “high” level was 
determined by summing all the variable results 
containing “high” level of the variable and 
subtracting the sum of variables containing “low” 
level of the variable from it. For example, the 
effect of increasing nature from “low” to “high” 
was determined by summing all the variable 
results of sample containing “high” level of the 
nature and subtracting the sum of sample 
containing “low” level of nature using the 





The amount by which the result of this treatment 
departed from zero irrespective of whether 
positive or negative is the quantitative measure 
of the individual effect of the variable on the 
diabetic control of the rats obtained from 
changing the nature. 
Similar expressions were applied to determine 
the individual effect of dose (C) and duration (D) 
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Determination of Interaction Effect 
This was used to determine whether there 
existed any interaction between the variables, 
and if there was, the trend for each drug-extract 
combination. To determine whether there exist 
any interaction between two variables, the 
results of the combination in which they 
appeared together at either ‘’high’’ (H) or ‘’low’’ 
(L) levels were summed, and the sum of the 
other combination subtracted from this to obtain 
the interaction coefficient. For example, to 
determine the interaction coefficient for nature 






A result of zero indicated no interaction, but if the 
interaction coefficient is significantly removed 
from zero, it is concluded that the two variables 
concerned were interacting with each other. The 
extent of removal from zero is a measure of the 
interaction. A positive value indicates an additive 
interaction, while a negative value indicates an 
opposing interaction. 
 
Statistical Analysis  
 Woolfall analysis was used to analyze the 
individual and interaction effects of the variables 
used in the study. Unpaired t-test was also used 
to determine level of significance of difference in 
blood glucose levels obtained with 
coadministration of Carica papaya leaf extract, 
and to evaluate effects of the extract on the 
activity of each oral hypoglycemic agent. At 95% 




The combinations obtained were grouped into 
appropriate sets which made it possible to 
assess the influence of each variable separately 
on the hypoglycemic activities of the drug-extract 
combinations, and to determine whether the 
variables were interacting or acting 
independently of one another, and also the 
combinations of variables that had the greatest 
influence on the interaction between the drug(s) 
and extract.  
Evaluating the effect of the individual variables, 
changing nature from “low” (Carica papaya 
extract) to “high” (drug) ranked lowest (Table 1) 
except at 12th and 72nd hr for glimepiride, and 
24th to 72nd hr for metformin. For both drugs, the 
dose C at which the extract/drug was 
administered was found to rank highest for the 
first 12  hr indicating that the dose at which the 
extract or drug was administered affected the 
activity more for the first 12 hr for glimepiride, 
and up to 24 hr for metformin (Table 1). The 
duration of administration had a significant effect 
on the activity of Glimepiride-extract and 
metformin-extract with a ranking of 
ND>CD>>NC (for the 2nd, 24th and 72nd hr), and 
CD>ND>NC (12th to the 72nd hr) respectively. 
The values for the various interactions were 
generally negative. The onset of hypoglycemic 
activity of leaf extract of Carica papaya was 
found to be around 24 hr irregardless of the 
dose. The activity was found to be significant at 
the 5mg/kg and comparable to glimepiride 
(0.2mg/kg) and metformin (50mg/kg) (Table 2) 
though with a longer onset of action than the 
drugs. The administration of the extract at 10 
mg/kg increased the onset of activity of 
glimepiride to 24 hr (Table 3). Generally, 
administration of “high” dose of the extract in 
combination with glimepiride increased the onset 
of activity compared with glimepiride 
monotherapy (p<0.01) after which there was a 
transient increase in blood glucose observed at 
72 hr followed by decrease in glucose levels 
(Table 4).  
The addition of the extract did not significantly 
affect the hypoglycemic effect of metformin 
except with high doses of both (p<0.05) at 2 hr 
and “high”-“low” metformin-extract at 12 hr 
(p<0.05). There was a highly significant 
reduction of blood glucose at 24 hr with all 
combinations thereafter (p<0.01) which 
extended to 72 hr except for the “low”-“low” 
combination. This effect on metformin activity 
was similar to what was observed with 
glimepiride except that the intensity of the effect 
was more obvious with metformin than with 
glimepiride.  
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Table 1: Effect of variables on blood glucose levels of animals (n=4)  
 
Time (hr Post Administration) Individual Variables 
Glimepiride/Extract 
2  hr 12  hr 24  hr 72  hr 
Nature -1.82 -6.74 0.54 -0.51 
Concentration -4.55 -2.95 -0.39 -0.37 
Duration 1.90 3.09 -0.55 -0.25 
Ranking  C>D=N N>D>C D=N>C N>C>D 
Metformin/Extract     
Nature 0.23 -1.57 3.42 2.03 
Concentration -2.24 -3.28 -0.17 -0.09 
Duration 1.11 3.18 -1.23 -1.32 
Ranking  C>D>N C>D>>N N>D>>C N>D>>C 
Time (hr Post Administration) Interacting Variables 
2  hr 12  hr 24  hr 72  hr 
Glimepiride/Extract     
N-C -0.28 3.24 -0.05 -0.04 
N-D -1.48 -3.05 0.51 0.21 
 
C-D 
1.04 -2.61 -0.49 -0.15 
Ranking ND>CD
>>NC 
NC>ND>CD ND=CD>>NC ND>CD>>NC 
Metformin/Extract  
N-C 1.82 2.72 0.17 0.17 
N-D -2.11 -2.85 0.76 0.21 
C-D 0.12 -3.33 -1.11 -0.87 
Ranking ND>NC
>>CD 
CD>ND>NC CD>ND>>NC CD>ND>NC 
 




     Table 2: Hypoglycemic effect of Carica papaya ethanolic leaf extract in diabetic rats (n=4)  
 
Blood glucose level (mmol/L)  hr post administration (mean ± standard deviation) Group/Treatmen
t 
Duration 
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Table 3: Hypoglycemic effect of the oral hypoglycemic agents in diabetic rats (n=4)  
 
Blood glucose level x  hr post treatments (mean ± standard deviation) Group/Treatment Duration 
(days) 0 hr 2 hr 12 hr 24 hr 72 hr 168 hr 
Glimepiride        
7 (High) 11.98±4.72 10.45±3.75 2.25±0.8 2.08±0.81 2.05±0.77 2.06±0.78 0.2mg/kg, low 
3 (Low) 11.4±4.65 10.55±3.96 2.23±0.54 2.23±0.79 2.18±0.78 ND 
7 (High) 8.9±2.22 6.15±1.12 2.56±1.32 1.75±0.70 1.73±0.56 1.83±0.66 0.4mg/kg, high 
3 (Low) 13.6±4.65 5.2±0.83 2.5±0.68 1.68±0.38 1.68±0.35 ND 
Metformin         
7 14.20±2.29 10.43±0.53 8.53±0.58 6.68±0.28 5.03±0.37 3.15±0.37 50mg/kg 
3 13.95±1.63 9.98±1.76 6.78±1.09 5.10±0.81 3.85±0.43 ND 
7 10.15±0.96 8.83±0.84 6.75±0.50 5.55±0.65 3.80±0.18 3.00±0.35 100mg/kg 
3 12.55±1.58 10.98±1.34 7.83±1.21 6.23±0.91 5.23±0.66 ND 
Key:  
Low = 3 days;   High =7days   
ND   = Not determined 
 
 
Table 4:  Effect of coadministration of extract of Carica papaya extract on hypoglycemic effect of  
glimepiride (n=4) for 7 days duration. 
Blood glucose levels (mmol/L)  hr post treatment (mean ± std deviation) Group Treatment/ 
Doses 2  hr 12  hr  24  hr 72  hr 168  hr 
0.2mg/kg (low) 10.50±1.26 2.24±0.24 2.13±0.26 2.11±0.26 2.08±0.39 Glimepiride 


















9.42±3.12* 9.28±3.28** 1.40±0.29 9.15±3.18** 4.35±2.56 
Metformin 50mg/kg (low) 10.43±0.53 8.53±0.58 6.68±0.28 5.03±0.37 3.15±0.37 


















18.33±6.00* 5.45±2.02 1.83±0.45** 1.55±0.24 3.73±0.61 
Key: 
*- p<0.05;   
** - p< 0.01   
***- p<0.005 – significant level when compared with drug alone 
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DISCUSSION  
The onset of hypoglycaemic activity of leaf 
extract of Carica papaya was as confirmed by a 
previous study 11. Generally, the extract of 
Carica papaya was as effective as glimepiride 
and metformin as hypoglycemic agent though 
the drugs had a faster onset of action.  
The ranking of the interacting variables showed 
that the interactions between the drugs and the 
extract were influenced by various interactions 
between the factors which may not be 
unconnected with the different mechanisms of 
action of the two drugs. Nature and 
concentration of drug administered interacted 
greatly with duration of administration, and the 
effect of ND and CD was much greater than NC 
to give a ranking of ND>CD>>NC for 
glimepiride-extract combination with nature and 
concentration having relatively negligible 
interaction. However, the effect of the duration of 
administration depended greatly on the nature 
and dose of the material being administered. 
This is to be expected since the duration would 
normally depend on some known properties of 
the active materials such as its strength of 
activity (nature) and on the concentration (dose) 
of the material in the dosage form or extract. 
Nature, and concentration, to a large extent 
functioned independently of each other showing 
that the dose of the drug/extract to be co 
administered will not be dependent on the 
nature. Metformin-extract, on the other hand, 
gave a more consistent ranking of CD>ND>NC 
showing that duration of administration also 
depended on the dose administered and nature 
as it did for the glimepiride-extract though in a 
reverse order.  NC was also shown to be 
independent of each other. The negative values 
suggest the complexity of interactions in the 
administered combinations.  
The tendency to increase the onset of action of 
glimepiride by the extract at a “high” dose of the 
extract for the first 24 hr might be due to delay in 
the absorption of the drug (since they were both 
administered orally) by initially binding up part of 
the drug and preventing it from getting into the 
systemic circulation from the gastrointestinal 
tract, or by stimulating the production and activity 
of enzymes that degrade some of the drug 
especially in the gut.  Generally, administration 
of the metformin-extract combination caused a 
more significant lowering of blood glucose when 
compared with metformin monotherapy at 
different periods of sampling exhibiting an 
additive effect as a result of interaction between 
the dose and duration of administration.   
The interaction between the drug-extract 
combinations was different for each drug. This 
could be due to the difference in mechanisms of 
action of metformin and glimepiride. Oke11 has 
proposed that the extract of Carica papaya 
lowers blood glucose in a similar manner to 
chlorpropamide. Glimepiride is known to lower 
glucose concentration in the blood, primarily by 
stimulating a first-phase release of insulin from 
functioning pancreatic beta-cells in response to 
food and causes an increased sensitivity of body 
cell to endogenous insulin, hence decreasing 
insulin resistance. Metformin on the other hand 
stimulates tissue uptake of glucose and 
increases insulin receptor binding.  
The observed interaction between the extracts of 
Carica papaya and glimepiride in diabetic rats 
could be said to lead to a delay in onset of action 
followed by a synergistic effect. A synergistic 
effect was observed with metformin.  
 
CONCLUSION 
The administration of Carica papaya leaf extract 
with glimepiride or metformin led to significant 
interactions which affected the oral 
hypoglycaemic activities of the drugs. There may 
be a need for more studies to evaluate the long 
term effect of the co administration of the extract 
and drug(s) so as to evaluate the problems 
involved in the practise, a need for public 
enlightenment on the dangers of co 
administration of extracts of Carica papaya with 
oral hypoglycemic or any other herbal product 
since this may lead to very low blood glucose as 
observed in this study.  Future studies may be 
directed towards elucidation of the pathway of 
mechanism of the interaction observed between 
each drug and the extract of Carica papaya.  
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